David Schull

Sigyn Therapeutics Launches Initiative to Evaluate Emerging Medical Technologies in Former NFL Players at Risk of CTE :: Sigyn Therapeutics, Inc. (SIGY) sigyntherapeutics.com/news-media/pre…

Priovant Expands Brepocitinib Development Program with New globenewswire.com/news-release/2…

Wugen Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of Soficabtagene Geleucel businesswire.com/news/home/2026…

PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio prnewswire.com/news-releases/…

FBLG: Advancing Fibroblast Therapy on Multiple Fronts finance.yahoo.com/sectors/health…

Health systems aren’t creating separate budgets for AI, instead, it’s being embedded into enterprise IT and evaluated alongside other core technology investments. Read about this shift in @BeckersHR by @NaomiCDiaz: bit.ly/4sHVpDL #HealthcareAI #DigitalHealth

Excited to see innovation at the forefront of #neuroscience and human health at this year’s @WestVirginiaU Public Education Collaborative "Focus Forward" conference. @JaymeStrauss, Chief Clinical Officer at Precision Neuroscience, and Dr. @PeterKonrad12, Chair of #Neurosurgery at WVU Medicine Health Sciences, will join Dr. @ClayMarsh, Chancellor and Executive Dean of @WVUhealth Sciences, for a compelling fireside chat: “Brain-Computer Interface: The Future of Mind-Reading Biotech is Here.” This conversation will explore how groundbreaking, first-of-its-kind clinical trials are leveraging globally unique neurotechnology to unlock new possibilities—bringing renewed hope for improved quality of life and transformative advances in human health. Learn more about the West Virginia Public Education Collaborative conference here:  go.wvu.edu/Focus26 #FocusForwardWV #BrainComputerInterface @PrecisionNeuro_

22,530 Americans are projected to hear the words “you have esophageal cancer” this year. But the number doesn’t capture the ripple effect — the families whose priorities shift overnight, the calendars filled with medical appointments, the lives that suddenly revolve around a diagnosis no one saw coming. What many people don’t know is that this deadly cancer begins with a detectable precancerous condition. And today, detection of this precancerous condition is possible with a two-minute test in your doctor's office. This #EsophagealCancerAwarenessMonth, we’re working to ensure those at highest risk have access to EsoGuard® — a test designed to detect esophageal precancer before cancer develops. Because cancer prevention begins with #EarlyDetection #CheckYourFoodTube #GetScreened

Attending #IAFFStrive? Firefighters face a 62% higher risk of developing esophageal cancer than the general population. Connect with the team from Lucid Diagnostics to learn how EsoGuard screening programs are already advancing firefighter cancer prevention efforts across the country. #FirefighterHealth #EarlyDetection

Korsana boosts #Alzheimer’s work with reverse #merger, $380M #financing bioworld.com/articles/729977 #biopharma

.@EliLillyandCo’s #Foundayo enters oral #GLP1 #obesity market with speedy @US_FDA nod (free w/one-time registration) bioworld.com/articles/72997… #biopharma #approval #orforglipron

Orforglipron -- now Foundayo -- is here cnbc.com/2026/04/01/eli…

Paragon launched its 7th company today -- Korsana Biosciences, merging into the $CYCN public shell. New ticker will be $KRSA. Lead drug candidate is a shuttled anti-amyloid beta antibody for Alzheimer's disease in early studies. ir.cyclerion.com/news-releases/…

There's a new AI lab with $1b of funding on the block: crypto billionaire @JedMcCaleb, founder of @Ripple and @StellarOrg, has committed $1b of his fortune to a nonprofit with the goal to build brain-inspired AGI: forbes.com/sites/annatong…

Emory University Board of Trustees elects new chair-elect news.emory.edu/stories/2026/0…

BioXcel Therapeutics Announces Food & Drug Administration globenewswire.com/news-release/2…

ReAlta Life Sciences names Berman CEO, Motesharei president By Investing.com au.investing.com/news/company-n…

Common vitamin may slow glioblastoma progression in patients, early study finds | Fox News foxnews.com/health/aggress…

NervGen Maps Path to Phase 3 as NVG-291 Data Strengthen Neuroreparative Ambitions - TipRanks.com tipranks.com/news/company-a…

Diakonos Oncology to Showcase DOC1021 (dubodencel) Clinical Data in Pancreatic Cancer and Glioblastoma at AACR and AAN 2026 - BioSpace biospace.com/press-releases…